Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.

ABSTRACT: The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI-insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment and are imperative for disease progression as well as recurrence during treatment-free remission (TFR). Here, we have generated high-resolution single-cell multiomics maps from CML patients at diagnosis, retrospectively stratified by BCR::ABL1^IS (%) following 12 months of TKI therapy. Simultaneous measurement of global gene expression profiles together with >40 surface markers from the same cells revealed that each patient harbored a unique composition of stem and progenitor cells at diagnosis. The patients with treatment f

SUBMITTER: Warfvinge R 

PROVIDER: S-EPMC11540304 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature